Singapore approves Moderna’s booster vaccine that targets original Covid-19 virus, Omicron variant
Add BT as a preferred source
THE Health Sciences Authority (HSA) on Wednesday (Sep 14) granted interim authorisation for the use of Moderna’s Spikevax bivalent Covid-19 vaccine, which targets both the original Sars-CoV-2 strain and the Omicron BA.1 variant.
The bivalent vaccine has been authorised for use as a booster for people aged 18 and above who have already received their primary series vaccination.
Official recommendations for this booster vaccine will be issued by the Expert Committee on Covid-19 Vaccination and the Ministry of Health in due time, HSA said.
The authority said it had consulted experts from its Medicines Advisory Committee and Panel of Infectious Diseases Experts in making its decision.
“HSA has carefully reviewed the data from Moderna’s pre-clinical studies, clinical trials in human volunteers, manufacturing and quality controls, and assessed that the benefits outweighed the risks for use of the bivalent vaccine as a booster to protect against Covid-19 as the virus continues to evolve,” it said. THE STRAITS TIMES
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Stocks to watch: ThaiBev, Genting Singapore, First Resources, Olam Group, UMS Integration, Frencken, SBS Transit and more
Olam H1 profit up six times to S$1.9 billion on Olam Agri spin-off; declares dividend of S$0.07 a share
